Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma
复制标题
DOI：
10.1200/jco.2005.01.6196
复制
发表时间：
2006-04-01
影响因子：
45.3
通讯作者：
Norris, MD
中科院分区：
文献类型：
--
作者：
Haber, M;Smith, J;Norris, MD
目的我们以前的一项回顾性研究表明，多药转运蛋白基因MRP 1（ABCC 1）的表达与神经母细胞瘤的预后有关。我们现在已经进行了一项前瞻性分析，以研究独立的预后意义的MRP1表达在一个大的队列的原发性未经治疗的神经母细胞瘤。患者和MethodsTwo百9诊断神经母细胞瘤样本的患者前瞻性地招募到儿科肿瘤组生物学协议9047进行了分析，MRP1，MDR1，MYCN，和TRKA基因的表达，使用实时聚合酶链反应。结果MRP1在所有分析的肿瘤中均有表达，且在MYCN扩增阳性的肿瘤中表达水平显著高于无MYCN扩增的肿瘤（P
PurposeWe have previously shown in a retrospective study,that expression of the multidrug transporter gene MRP1 (ABCC1) is associated with outcome in neuroblastoma. We have now undertaken a prospective analysis to examine the independent prognostic significance of MRP1 expression in a large cohort of primary untreated neuroblastomas.Patients and MethodsTwo hundred nine diagnostic neuroblastoma samples from patients prospectively enrolled onto the Pediatric Oncology Group biology protocol 9047 were analyzed for expression of the MRP1, MDR1, MYCN, and TRKA genes using real-time polymerase chain reaction. Expression levels were correlated with established prognostic indicators and disease outcome.ResultsMRP1 expression was detected in all tumors analyzed, and levels were significantly higher in tumors with versus without MYCN amplification (P